HIV therapy has mostly been through drugs up to now. PEMF therapy might be a welcome addition to the drug treatments.
Due to advances in antiretroviral drug treatment over the past 20 years, most people with HIV can now expect to live long, healthy lives.
However, even if treatment successfully brings the virus under control, people can experience cognitive issues as a result of HIV causing damage to their central nervous system.
Up to 45% of people with HIV may develop these difficulties, which are known collectively as HIV-associated neurocognitive disorder (HAND).
The Cause of HAND in HIV patients
Although the cause of HAND remains unknown, scientists have several theories. They speculate, for example, that it may be the result of chronic inflammation, lingering damage from the initial infection, or a toxic effect of antiretroviral drugs.
Alternatively, low levels of the virus may persist in the brain as a result of the blood-brain barrier limiting the passage of antiretroviral drugs into the brain.
The signs and symptoms of HAND can be subtle, which makes it challenging for doctors to diagnose early and monitor.
Dealing with remaining HIV treatment toxins and the virus in the brain.
First the chronic inflammation can be dealt with by applying pulsing magnetic therapies like PEMF and LFMT.
Secondly, PEMF is well known through clinical studies for thinning the artery walls and increasing blood flow to the brain. PEMF also massively assists in the detox process and by combining this therapy with detoxing carriers like chlorella, it will enhance the cognitive detox and recovery of the brain.
Common speech sounds
The researchers recorded the FFR while the study participants listened to common speech sounds, such as “ba,” “da,” and “ga.”
They looked at how well the signal encoded two acoustic features of speech, known as the harmonics corresponding to the first formant and fundamental frequency.
The harmonics corresponding to the first formant identify the units of sound, or “phonemes,” that differentiate one word from another, whereas the fundamental frequency reflects the frequency at which the vocal cords vibrate, which helps identify the speaker.
The brains of people with HIV had similar responses to the brains of people without HIV at processing the fundamental frequency.
They also performed well on standard tests of hearing, but the FFR revealed that the brains of people with HIV were worse at encoding the first formant.
In other words, they had normal hearing thresholds, but their brains could not distinguish between the sounds of different words as accurately.
“When the brain processes sound, it’s not like a volume knob where all of the acoustic ingredients are either processed well or poorly,” Kraus explains. “With the FFR, we’re able to see which aspects of auditory processing are affected or diminished and ask, ‘[I]s there a specific neural signature that aligns itself with HIV?’”
Early aging
The researchers note that as people get older, even if their hearing remains normal, their brains get worse at processing the same speech features that the brains of people with HIV seem to struggle with.
They write that HIV-associated cognitive problems may therefore be akin to early aging.
In the future, they hope that other scientists will use the FFR not only to study brain dysfunction associated with HIV, but also other conditions, such as concussion and Alzheimer’s disease.
Standard tests of cognitive function involve giving people tasks, such as solving math problems or remembering a list of words. However, these are dependent on the language people speak and their culture.
“What’s significant about our results is that the test doesn’t require any actions on the [subject’s] part. It’s recorded passively — subjects can even sleep or watch a movie,” says Dr. Buckey. “We think the FFR holds a lot of promise as a way to assess the brain easily and objectively.”
In their paper, the researchers note that the test could prove particularly useful in parts of the world with the most HIV infections and limited healthcare resources.
They write, “While previous neuroimaging and electrophysiological studies have shown differences between HIV+ and HIV- individuals, these approaches are difficult to transport to resource-limited settings such as sub-Saharan Africa, where >70% of the world’s HIV+ population lives and where there is some evidence that neurocognitive symptoms are more severe.”
“Thus, the FFR holds promise as a research tool to further study [central nervous system] health, particularly in resource-limited settings.”
The study authors acknowledge that research projects involving more participants will be necessary to confirm their results. They say that it would also be interesting to track changes in the FFR from the early stages of infection onward.
MEDICALNEWSTODAY